Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

被引：0
|
作者：
E Van Cutsem
C-P Li
E Nowara
G Aprile
M Moore
I Federowicz
J-L Van Laethem
C Hsu
C K Tham
S M Stemmer
R Lipp
A Zeaiter
A Fittipaldo
Z Csutor
B Klughammer
X Meng
T Ciuleanu
机构：
[1] Gastroenterology/Digestive Oncology,Division of Gastroenterology, Department of Medicine
[2] University Hospitals Leuven and KU Leuven,Department of Medical Oncology
[3] Taipei Veterans General Hospital,Division of Medical Oncology and Hematology
[4] National Yang-Ming University School of Medicine,Department of Gastroenterology
[5] Centrum Onkologii—Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach,GI Cancer Unit
[6] ul. Wybrzeże Armii Krajowej 15,Department of Medical Oncology
[7] University Hospital of Udine,undefined
[8] Princess Margaret Hospital,undefined
[9] NZOZ Magodent,undefined
[10] Erasme University Hospital-ULB-Brussels,undefined
[11] National Taiwan University Hospital,undefined
[12] National Cancer Center Singapore,undefined
[13] Institute of Oncology,undefined
[14] Davidoff Center,undefined
[15] Rabin Medical Center,undefined
[16] GermanOncology GmbH,undefined
[17] Roche Products Ltd,undefined
[18] F. Hoffmann-La Roche,undefined
[19] PD Biostatistics,undefined
[20] Roche,undefined
[21] Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
pancreatic cancer; erlotinib; epidermal growth factor; oncology; dose; rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2067 / 2075
页数：8
相关论文
共 50 条
  • [31] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Heloisa P. Soares
    Soley Bayraktar
    Marcelo Blaya
    Gilberto Lopes
    Jaime Merchan
    Jessica Macintyre
    Carlos Mayo
    Mark R. Green
    Orlando Silva
    Joe Levi
    Gail Walker
    Caio M. Rocha-Lima
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 839 - 845
  • [32] Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
    A C Mita
    K Papadopoulos
    M J A de Jonge
    G Schwartz
    J Verweij
    M M Mita
    A Ricart
    Q S-C Chu
    A W Tolcher
    L Wood
    S McCarthy
    M Hamilton
    K Iwata
    B Wacker
    K Witt
    E K Rowinsky
    British Journal of Cancer, 2011, 105 : 938 - 944
  • [33] Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
    Mita, A. C.
    Papadopoulos, K.
    de Jonge, M. J. A.
    Schwartz, G.
    Verweij, J.
    Mita, M. M.
    Ricart, A.
    Chu, Qs-C
    Tolcher, A. W.
    Wood, L.
    McCarthy, S.
    Hamilton, M.
    Iwata, K.
    Wacker, B.
    Witt, K.
    Rowinsky, E. K.
    BRITISH JOURNAL OF CANCER, 2011, 105 (07) : 938 - 944
  • [34] GEMCITABINE (GEM) PLUS CELECOXIB IN ADVANCED PANCREATIC CANCER: A PHASE II STUDY
    Valcamonico, F.
    Ferrari, V. D.
    Simoncini, E.
    Amoroso, V.
    Vassalli, L.
    Rangoni, G.
    Grisanti, S.
    Marpicati, P.
    Marini, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [35] Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)
    Lopez, Rafael
    Mendez Mendez, Carlos
    Jorge Fernandez, Monica
    Romero Reinoso, Carlos
    Quintero Aldana, Guillermo
    Salgado Fernandez, Mercedes
    De La Camara Gomez, Juan
    Reboredo Lopez, Margarita
    Ramos Vazquez, Manuel
    Candamio Folgar, Sonia
    ANTICANCER RESEARCH, 2013, 33 (02) : 717 - 723
  • [36] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
  • [37] Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Philip Q. Bao
    Ramesh K. Ramanathan
    Alyssa Krasinkas
    Nathan Bahary
    Barry C. Lembersky
    David L. Bartlett
    Steven J. Hughes
    Kenneth K. Lee
    A. James Moser
    Herbert J. Zeh
    Annals of Surgical Oncology, 2011, 18 : 323 - 323
  • [38] A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
    Van Cutsem, E.
    Verslype, C.
    Beale, P.
    Clarke, S.
    Bugat, R.
    Rakhit, A.
    Fettner, S. H.
    Brennscheidt, U.
    Feyereislova, A.
    Feyereislova, A.
    Delord, J. -P.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 332 - 339
  • [39] Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial
    Westphalen, C. Benedikt
    Heinemann, Volker
    Tessen, Hans Werner
    Groschek, Matthias
    Hoeffkes, Heinz-Gert
    Marschner, Norbert
    Schulze, Mathias
    Beringer, Andreas
    Waldschmidt, Dirk
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (04): : 332 - 340
  • [40] Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer
    Jiang, Yixing
    Mackley, Heath B.
    Kimchi, Eric T.
    Zhu, Junjia
    Gusani, Niraj
    Kaifi, Jussuf
    Staveley-O'Carroll, Kevin F.
    Belani, Chandra P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 205 - 210
12345